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Abstract
The hallmarks of human malignant gliomas are their marked invasiveness and vascularity. Because angiogenesis
and tumor invasion have been associated with extracellular matrix degradation and intercellular tight junctions, the
involvement of zonulin in glioma biology is in the focus. We selected for histological examination five cases of
glioblastoma WHO IV (nomenclature of the World Health Organization) and one case each from astrocytoma
WHO III, meningioma WHO III, and meningioma WHO I as control samples. The meningioma WHO I is regarded
as benign, whereas the meningioma WHO III is recognized as the transition form of malignant tumors in humans.
The visualization of a newly designed antibody against human zonulin was studied in triple-labeling studies using
fluorescence immunocytochemistry and compared with the expression of c-kit and glial fibrillary acidic protein in
differently developed human gliomas. We found that increasing the expression of c-kit is accompanied by an in-
crease of zonulin expression. Both are correlated to the degree of malignancy of human brain tumors. The expres-
sion of zonulin is correlated to the degradation of the blood-brain barrier as revealed by Griffonia simplicifolia lectin.
In differently graded tumors, we found differently graded involvement of blood vessels in the tumor development,
explaining patients’ survival.
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Introduction
The regulation of intercellular tight junctions in the intestinal epithe-
lium by zonulin is well known. It is conceivable that zonulin partic-
ipates under physiological conditions not only in the small intestine
[1,2] but also throughout a wide range of extraintestinal epithelia as
well as the ubiquitous vascular endothelium, including the blood-
brain barrier [3]. Dysregulation of this hypothetical zonulin model
may contribute to disease states that involve disordered intercellular
communication, including malignant transformation, which leads to
new therapy options in oncology. Down-regulation of zonulin may
inhibit tumor-mediated angiogenesis and glioma growth in vivo.
That scenario had been proven for c-kit expression. Both zonulin
and the c-kit pathway play important roles in tumor-induced angio-
genesis. Primary human gliomas express c-kit in a grade-dependent
manner and induce normal neurons to express c-kit in brain regions
infiltrated by glioma cells, areas that colocalize with prominent angio-
genesis. Overexpression of c-kit is associated with a shorter survival in
patients with malignant gliomas [4]. Thus, the c-kit pathway plays an
important role in tumor-induced angiogenesis within the brain. The
inhibition of c-kit by synthetic small molecules has become a prom-
ising new therapy option in oncology [4]. The authors reported
about therapy responders and nonresponders. Statistical analysis
did not reveal any correlation between expression of tyrosine kinase
receptors (e.g., c-kit) and patients’ survival. Maybe the relevant link
in the therapy chain is the tight junction of the blood-brain barrier.
Here, we try to provide evidence for the graded expression of both
zonulin and c-kit in differently graded tumors. Glial fibrillary acidic
protein (GFAP) was used as another tumor and degeneration marker.
Blood vessels are revealed by Griffonia simplicifolia lectin (GSI).
Materials and Methods
Samples
All procedures used in the present study were approved by the
Ethics Committee of the University of Leipzig (no. 086-2008).
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The rules of the Declaration of Helsinki from 1975 (revised in 1983)
were followed. All procedures were carried out with the understand-
ing and written consent of the subjects. A total of eight human bi-
opsies were used. Five cases of glioblastoma WHO IV and one case
each of astrocytoma WHO III, meningioma WHO III, and menin-
gioma WHO I as control samples were selected for histological eval-
uation. The meningioma WHO I is regarded as benign, whereas the
meningioma WHO III is reckoned as the transition form of malig-
nant tumors in humans. The most aggressive tumor of the sample is
the glioblastoma WHO IV.
Native frozen sections (8 μm) were cut on a cryotome. A Cy3-
conjugated antibody against GFAP was used to reveal the tumor ex-
tension, lectin histochemistry for the visualization of blood vessels,
and immunohistochemistry for c-kit and zonulin was performed on
serially cut sections as detailed later. Certain sections were double-
stained with GSI and antibodies directed against GFAP, c-kit, and
zonulin, respectively, to reveal a correlation of those markers. Most
of the sections were counterstained with 4′,6-diamidino-2-phenylindol
(Serva) for nuclei labeling.
GSI Histochemistry
After two rinses with PBS followed by two rinses with 0.05 M
Tris-HCl + 0.9% NaCl (TBS), the sections were incubated with bio-
tinylated GSI (b-GSI, L-1766; Sigma, Munich, Germany) at a con-
centration of 10 μg of b-GSI/ml TBS containing 2% bovine serum
albumin (TBS-BSA) overnight at 4°C. Sections were rinsed four
times (15 minutes each) with TBS and further incubated for 1 hour
in streptavidin-Cy3 or streptavidin-Cy2 (20 μg/ml; Dianova, Hamburg,
Germany), rinsed, and double-stained immunohistochemically or dried
and coverslipped.
Figure 1. Lower (A) and higher magnifications (B) of the expression of c-kit (red) in the cytoplasm of glioblastoma WHO IV, DAPI counter-
stainings of cell nuclei (blue) display signs of proliferation. Triple stainings of astocytoma WHO III: red indicates c-kit expression (arrows),
green at the periphery reveals zonulin expression, and DAPI labels the cell nuclei blue (C). The meningioma WHO I was used as control:
some green-colored zonulin expression is displayed only; double staining for both c-kit and zonulin expression (D). Comparison of the
meningioma WHO I (E) and WHO III (F) by the expression of zonulin and binding sites of GSI agglutinin indicating degraded and normal
blood-brain barrier: the benign meningioma shows normally developed endothelium (green) and extremely few degradations of that (re-
vealed by the expression of zonulin, red), whereas the normal feature of the endothelium of the blood-brain barrier disappears in menin-
gioma WHO III and some more red-colored zonulin expression is visible (arrows).
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Immunohistochemistry
After blocking with goat normal serum, the sections were treated
with the primary antibody against c-kit (developed in mouse) and
zonulin (newly designed by Immundiagnostik AGBensheim, Germany;
developed in rabbit). Fluorescence immunoreactivities were visualized
by means of Cy3-conjugated goat-antimouse antibody (diluted 1:150;
Dianova) and/or Cy3-, Cy2-conjugated donkey-antirabbit or goat-
antirabbit, respectively.
Control sections were treated similarly but using a nonspecific
mouse or rabbit IgG1 (DAKO, Cologne, Germany) instead of primary
antibodies. Fluorescence of sections was studied microscopically with a
photomicroscope “Axiophot” (Zeiss, Jena, Germany) equipped with
epifluorescence.
For double or triple stainings, we combined the secondary anti-
bodies avoiding the use of two identical color conjugations and same
host species.
Results
All stagings of tumors that were revealed by the expression of c-kit
(Figure 1, A–C ) were also revealed by zonulin expression. Neverthe-
less, there are some differences:
We did not find any expression of c-kit, but some expression of
zonulin in meningioma WHO I (Figure 1D). In the sample of me-
ningioma WHO III, both c-kit and zonulin were expressed. To some
extent, we further found a colocalization of those.
Comparison of meningioma WHO I and WHO III by the expres-
sion of zonulin and binding sites of GSI agglutinin indicated normal
and degraded blood-brain barrier. Whereas the benign meningioma
showed normally developed endothelium and extremely few degrada-
tion, the normal feature of the endothelium of the blood-brain bar-
rier disappeared in meningioma WHO III (Figure 1, E and F ).
The expression of GFAP displayed no colocalization with c-kit and
zonulin (Figure 2, A and B) with the exception of GFAP localization
at the walls of the blood vessels (Figure 2B).
All features of the starting degradation of blood vessels are revealed
by binding sites of GSI agglutinin in astrocytoma WHO III. The
development of disturbance of blood vessels was shown in Figure 2,
C and D, displaying nearly all stages of alterations of the blood-brain
barrier in glioblastoma WHO IV. Here, we found colocalization of
zonulin and binding sites of GSI agglutinin (indicated by white-yellow
color, which was the result of both red and green fluorescence).
There is some evidence from our immunocytochemical studies that
Figure 2. Lower (A) and higher magnifications (B) of the expression of GFAP (red) and expression of zonulin (green) in glioblastoma WHO
IV: no colocalization. Features for starting of degradation (green) of blood vessels (indicated by binding site of GSI agglutinin, red) in
astocytoma WHO III: no colocalization (C, arrows in D). (E) Alterations of the blood-brain barrier in glioblastoma WHO IV. White-yellow:
colocalization of binding sites of GSI agglutinin and zonulin.
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the expression of zonulin correlated with the aggressivity of the tu-
mor in a more specialized way than the expression of c-kit. Zonulin
expression could clearly indicate the degree of the disturbance of the
blood-brain barrier and the walls of the blood vessels, respectively
(Figure 2, D and E ).
Discussion
Zonulin was firstly described as zonula occludens toxin (zot). It is
produced by Vibrio cholerae and has the ability to increase mucosal
permeability by reversibly affecting the structure of tight junctions
[5–9]. Even Fasano [7] suggested that this characteristic of zonulin
could work also throughout a wide range of extraintestinal epithelia
as well as the ubiquitous vascular endothelium, including the blood-
brain barrier. Dysregulation (both over and under expression) may
contribute to disease states that involve disordered intercellular com-
munication [10] including malignant transformation and metastasis.
Here, we tested that hypothesis by comparing the zonulin expression
with established markers of human glial tumors such as c-kit and
GFAP [11,12]. The correlation to blood vessels or rather the blood-
brain barrier was studied by the binding sites of GSI agglutinin.
Glial fibrillary acidic protein is a common marker for glial cells
regardless of their origin and developmental status. We used this
marker to identify possible necrosis when expressed without any vas-
cularity in the vicinity.
The gene product of c-kit has been shown to be expressed in cells
of glial tumors with higher malignancy [13]. The authors found a
preferred occurrence in both cells of pericyte or fibroblast morphol-
ogy and in few neoplastic cells of overt astrocyte morphology. Cetin
et al. [14] investigated 52 glial tumors of various histologic types and
grades and found that 75% of the specimens were positive for the
c-kit product. The proportion of high-grade tumors was statistically
significantly greater than low-grade tumors; glioblastoma revealed the
highest degree of c-kit expression. These results were supported by
our findings. The new suggested perspective on these results is
strongly supported by the zonulin expression in glial tumors, firstly
reported here. If the aggressivity of the tumor depends on an in-
creased expression of c-kit and its activated form, which is supported
by the fact that both are increased frequently in glioblastoma [15],
then the intercellular communication plays the key role [16]. The
intercellular communication is under the control of zonulin. The dif-
ferent responsiveness of glioblastomas to specific tyrosine kinase in-
hibitors as targets for therapy could be explained by the somewhat
different expression of zonulin compared with the expression of
c-kit in glioblastomas. In conclusion, the estimation of zonulin ex-
pression could be helpful for therapy decision and success. By study-
ing these parameters simultaneously in a large number of the same
tumor samples, we hope to clarify their respective contributions to
the aggressiveness of human gliomas.
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